Paper. Cancer Discovery, 1 Oct 2026.
Tags: LSD, Cancer.
A PNAS study strips LSD down to its minimal pharmacophore and finds safer, less hallucinogenic analogues.
Nine simplified ergolines were profiled across 5-HT2A/2B/2C; UCD0076 prefers 5-HT2C, shows antipsychotic-like effects in mice and avoids LSD's cardiotoxic liability. A separate report has a non-hallucinogenic LSD analogue boosting anti-tumour immunity in colorectal cancer models.
Psilocybin prevented chemotherapy nerve damage in mice without blunting the chemo.
Two doses before platinum- or taxane-based chemotherapy preserved tactile sensitivity and nerve fibre endings by keeping mitochondria moving along axons, and an accompanying Science commentary frames this as prophylaxis rather than treatment. A separate Cancer Discovery paper reports a non-hallucinogenic LSD analogue boosting the immune response to colorectal cancer; both results are preclinical.